We are live on ! Find out more
MC

Muhlenkamp & Co Portfolio holdings

AUM $380M
1-Year Est. Return 43.74%
This Fund
S&P 500
This Quarter Est. Return
+10.45%
1 Year Est. Return
+43.74%
3 Year Est. Return
+121.38%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$229M
AUM Growth
+$23.7M
Cap. Flow
+$6.7M
Cap. Flow %
2.93%
Top 10 Hldgs %
47.55%
Holding
39
New
5
Increased
18
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$7.06M
2
DOW icon
Dow Inc
DOW
+$5.74M
3
LEN icon
Lennar Class A
LEN
+$5.42M
4
TEN
Tenneco Inc. Class A Voting Common Stock
TEN
+$4.9M
5
CVS icon
CVS Health
CVS
+$2.56M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$7.02M
2
GILD icon
Gilead Sciences
GILD
+$6.07M
3
CTSH icon
Cognizant
CTSH
+$5.3M
4
CCJ icon
Cameco
CCJ
+$4.3M
5
MSFT icon
Microsoft
MSFT
+$1.34M

Sector Composition

Rank Sector Weight
1 Technology 22.42%
2 Healthcare 22.38%
3 Consumer Discretionary 14.7%
4 Industrials 11.52%
5 Financials 7.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
1
Apple
AAPL
$4.9T
$17.3M 7.56%
235,496
-16,196
-6% -$1.04M
MSFT icon
2
Microsoft
MSFT
$2.93T
$16M 7%
101,622
-9,106
-8% -$1.34M
GLD icon
3
SPDR Gold Trust
GLD
$130B
$11.9M 5.19%
83,028
+68
+0.1% +$9.5K
RUSHA icon
4
Rush Enterprises Class A
RUSHA
$5.98B
$11.6M 5.08%
562,475
+202
+0% +$3.93K
MCHP icon
5
Microchip Technology
MCHP
$44B
$9.96M 4.35%
190,130
-108
-0.1% -$5.22K
MCK icon
6
McKesson
MCK
$98.5B
$9.76M 4.26%
70,541
+3
+0% +$424
BRK.B icon
7
Berkshire Hathaway Class B
BRK.B
$1.06T
$8.23M 3.6%
36,318
-4
-0% -$869
DOW icon
8
Dow Inc
DOW
$21.6B
$8.15M 3.56%
148,841
+111,193
+295% +$5.74M
AMLP icon
9
Alerian MLP ETF
AMLP
$12.7B
$8M 3.5%
188,286
+31,966
+20% +$1.34M
CVS icon
10
CVS Health
CVS
$137B
$7.91M 3.46%
106,514
+36,479
+52% +$2.56M
BMY icon
11
Bristol-Myers Squibb
BMY
$124B
$7.91M 3.46%
+123,223
New +$7.06M
AVGO icon
12
Broadcom
AVGO
$1.76T
$7.62M 3.33%
241,180
+39,450
+20% +$1.2M
BFH icon
13
Bread Financial
BFH
$4.01B
$7.59M 3.32%
84,762
-1,244
-1% -$110K
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.5B
$7.41M 3.24%
49,626
+13,384
+37% +$1.82M
LMT icon
15
Lockheed Martin
LMT
$117B
$7.36M 3.21%
18,889
+1
+0% +$384
MTH icon
16
Meritage Homes
MTH
$4.95B
$7.2M 3.14%
235,518
-12
-0% -$412
NLY icon
17
Annaly Capital Management
NLY
$16.9B
$7.15M 3.12%
189,721
+37
+0% +$1.35K
DAL icon
18
Delta Air Lines
DAL
$55.4B
$6.69M 2.92%
114,371
+41
+0% +$2.3K
CI icon
19
Cigna
CI
$74.5B
$6.37M 2.78%
31,131
+609
+2% +$112K
CE icon
20
Celanese
CE
$5.01B
$6.07M 2.65%
49,326
+63
+0.1% +$7.75K
AYI icon
21
Acuity Brands
AYI
$9.99B
$5.93M 2.59%
42,970
– –
BIIB icon
22
Biogen
BIIB
$30.4B
$5.27M 2.3%
17,768
-6
-0% -$1.67K
LEN icon
23
Lennar Class A
LEN
$20.2B
$5.14M 2.24%
+95,098
New +$5.42M
TEN
24
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
$4.9M 2.14%
+373,957
New +$4.9M
AZO icon
25
AutoZone
AZO
$49.7B
$4.57M 2%
3,835
+6
+0.2% +$6.93K
1
2

Similar funds

AC
Attestor Capital Grand Cayman, Cayman Islands $380M AUM
MW
Marks Wealth Annapolis, Maryland $380M AUM 40.02% 1-Year Est. Return
EAM
Empirical Asset Management Wellesley, Massachusetts $379M AUM 24.52% 1-Year Est. Return
RWA
Rooted Wealth Advisors Bourbonnais, Illinois $379M AUM 13.75% 1-Year Est. Return
CSWG
Cardinal Strategic Wealth Guidance Louisville, Kentucky $379M AUM 19.59% 1-Year Est. Return
BP
BWM Planning The Woodlands, Texas $379M AUM 21.72% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
KFS
Kurt F. Somerville $379M AUM 19.42% 1-Year Est. Return

Muhlenkamp & Co's Q4 2019 Portfolio in Review

As of Q4 2019, Muhlenkamp & Co held 39 positions worth $229M, up 12% from $205M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Muhlenkamp & Co's Q4 2019 filing shows 5 new, 18 increased, 11 reduced and 2 closed positions. Its largest new stake was Bristol-Myers Squibb: 123,223 shares worth $7.91M. The largest sale was Celgene Corp, an estimated $7.02M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Muhlenkamp & Co's largest Q4 2019 buy was Bristol-Myers Squibb: 123,223 shares worth $7.91M.
  • Muhlenkamp & Co added most to Dow Inc in Q4 2019, an estimated $5.74M increase.
  • Muhlenkamp & Co's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $6.07M.
  • Muhlenkamp & Co fully exited Celgene Corp in Q4 2019, selling an estimated $7.02M.
  • Muhlenkamp & Co's ten largest holdings make up 48% of its $229M portfolio in Q4 2019.
  • Muhlenkamp & Co opened 5 new positions and closed 2 in Q4 2019.
  • Muhlenkamp & Co's portfolio value rose 12% quarter-over-quarter to $229M.

Based on Muhlenkamp & Co's 13F filing for Q4 2019, filed 20 Feb 2020.